These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 36557281)

  • 21. Higher Trimethylamine-
    Rath S; Rox K; Kleine Bardenhorst S; Schminke U; Dörr M; Mayerle J; Frost F; Lerch MM; Karch A; Brönstrup M; Pieper DH; Vital M
    mSystems; 2021 Oct; 6(5):e0094521. PubMed ID: 34519520
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Molecular and Mechanistic Insights Based on Gut-Liver Axis: Nutritional Target for Non-Alcoholic Fatty Liver Disease (NAFLD) Improvement.
    Ji Y; Yin Y; Sun L; Zhang W
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32357561
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gut microbiota-associated trimethylamine N-oxide and increased cardiometabolic risk in adults: a systematic review and dose-response meta-analysis.
    Abbasalizad Farhangi M; Vajdi M
    Nutr Rev; 2021 Aug; 79(9):1022-1042. PubMed ID: 33270896
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel findings of the association between gut microbiota-derived metabolite trimethylamine
    Farhangi MA; Vajdi M
    Crit Rev Food Sci Nutr; 2020; 60(16):2801-2823. PubMed ID: 32462890
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Resveratrol Attenuates Trimethylamine-N-Oxide (TMAO)-Induced Atherosclerosis by Regulating TMAO Synthesis and Bile Acid Metabolism via Remodeling of the Gut Microbiota.
    Chen ML; Yi L; Zhang Y; Zhou X; Ran L; Yang J; Zhu JD; Zhang QY; Mi MT
    mBio; 2016 Apr; 7(2):e02210-15. PubMed ID: 27048804
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Effects of Statin Therapy on Circulating Levels of Trimethylamine N-oxide: A Systematic Review and Meta-analysis.
    Jamialahmadi T; Reiner Ž; Matbou Riahi M; Kesharwani P; Eid AH; Tayarani-Najaran Z; Sahebkar A
    Curr Med Chem; 2023 Oct; ():. PubMed ID: 37855344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interventions for non-alcoholic liver disease: a gut microbial metabolites perspective.
    Guo J; Shi CX; Zhang QQ; Deng W; Zhang LY; Chen Q; Zhang DM; Gong ZJ
    Therap Adv Gastroenterol; 2022; 15():17562848221138676. PubMed ID: 36506748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The heart and gut relationship: a systematic review of the evaluation of the microbiome and trimethylamine-N-oxide (TMAO) in heart failure.
    Anderson KM; Ferranti EP; Alagha EC; Mykityshyn E; French CE; Reilly CM
    Heart Fail Rev; 2022 Nov; 27(6):2223-2249. PubMed ID: 35726110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Trimethylamine-N-oxide (TMAO) mediates the crosstalk between the gut microbiota and hepatic vascular niche to alleviate liver fibrosis in nonalcoholic steatohepatitis.
    Zhou D; Zhang J; Xiao C; Mo C; Ding BS
    Front Immunol; 2022; 13():964477. PubMed ID: 36072588
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The microbial metabolite trimethylamine-N-oxide in association with inflammation and microbial dysregulation in three HIV cohorts at various disease stages.
    Missailidis C; Neogi U; Stenvinkel P; Trøseid M; Nowak P; Bergman P
    AIDS; 2018 Jul; 32(12):1589-1598. PubMed ID: 29620717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies.
    Qi J; You T; Li J; Pan T; Xiang L; Han Y; Zhu L
    J Cell Mol Med; 2018 Jan; 22(1):185-194. PubMed ID: 28782886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fecal Microbiota in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: A Systematic Review.
    Mohammadi Z; Poustchi H; Motamed-Gorji N; Eghtesad S; Hekmatdoost A; Saniee P; Merat S
    Arch Iran Med; 2020 Jan; 23(1):44-52. PubMed ID: 31910634
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small molecule inhibition of gut microbial choline trimethylamine lyase activity alters host cholesterol and bile acid metabolism.
    Pathak P; Helsley RN; Brown AL; Buffa JA; Choucair I; Nemet I; Gogonea CB; Gogonea V; Wang Z; Garcia-Garcia JC; Cai L; Temel R; Sangwan N; Hazen SL; Brown JM
    Am J Physiol Heart Circ Physiol; 2020 Jun; 318(6):H1474-H1486. PubMed ID: 32330092
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Trimethylamine N-Oxide, a Gut Microbiota-Derived Metabolite, Is Associated with Cardiovascular Risk in Psoriasis: A Cross-Sectional Pilot Study.
    Sikora M; Kiss N; Stec A; Giebultowicz J; Samborowska E; Jazwiec R; Dadlez M; Olszewska M; Rudnicka L
    Dermatol Ther (Heidelb); 2021 Aug; 11(4):1277-1289. PubMed ID: 33983475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis.
    Schiattarella GG; Sannino A; Toscano E; Giugliano G; Gargiulo G; Franzone A; Trimarco B; Esposito G; Perrino C
    Eur Heart J; 2017 Oct; 38(39):2948-2956. PubMed ID: 29020409
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Trimethylamine-N-Oxide Pathway: A Potential Target for the Treatment of MAFLD.
    Li X; Hong J; Wang Y; Pei M; Wang L; Gong Z
    Front Mol Biosci; 2021; 8():733507. PubMed ID: 34660695
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Metagenomic identification of gut microbiota distribution on the colonic mucosal biopsy samples in patients with non-alcoholic fatty liver disease.
    Delik A; Dinçer S; Ülger Y; Akkız H; Karaoğullarından Ü
    Gene; 2022 Jul; 833():146587. PubMed ID: 35598686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral and Gut Microbial Dysbiosis and Non-alcoholic Fatty Liver Disease: The Central Role of
    Wang T; Ishikawa T; Sasaki M; Chiba T
    Front Med (Lausanne); 2022; 9():822190. PubMed ID: 35308549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gut Microbiota-Dependent Trimethylamine N-Oxide Associates With Inflammation in Common Variable Immunodeficiency.
    Macpherson ME; Hov JR; Ueland T; Dahl TB; Kummen M; Otterdal K; Holm K; Berge RK; Mollnes TE; Trøseid M; Halvorsen B; Aukrust P; Fevang B; Jørgensen SF
    Front Immunol; 2020; 11():574500. PubMed ID: 33042155
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Contribution of gut microbiota to nonalcoholic fatty liver disease: Pathways of mechanisms.
    Bakhshimoghaddam F; Alizadeh M
    Clin Nutr ESPEN; 2021 Aug; 44():61-68. PubMed ID: 34330514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.